Sugi Predict

Sugi Predict / Compounds / SCHEMBL9896148

SCHEMBL9896148

SCHEMBL9896148

CS(=O)(=O)N1CCN(Cc2cc(F)cnc2Oc2ccc3c(nnn3CC3CC3)c2Cl)CC1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CCR3 P51677 2/20 0.39
▸ GRM2 Q14416 7/20 0.38
▸ SUV39H2 Q9H5I1 2/20 0.35
▸ PTGDR2 Q9Y5Y4 1/20 0.34
▸ PDCD1 Q15116 1/20 0.34
▸ CD274 Q9NZQ7 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ MAPK14 Q16539 1/20 0.33
▸ CNR1 P21554 1/20 0.33
▸ TNF P01375 1/20 0.33
▸ LITAF Q99732 1/20 0.33
▸ CCR5 P51681 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.32
▸ LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9895985 0.93 GRM2 (0.37) CCR3GRM2SUV39H2PTGDR2PDCD1
SCHEMBL9895038 0.91 GRM2 (0.39) CCR3GRM2KDM4EALOX15HTT
SCHEMBL9895151 0.85 GRM2 (0.38) GRM2SUV39H2PTGDR2KDM4EALOX15
SCHEMBL9897096 0.85 GRM2 (0.38) CCR3GRM2SUV39H2PTGDR2KDM4E
SCHEMBL9894761 0.83 GRM2 (0.36) GRM2SUV39H2PTGDR2KDM4EALOX15
SCHEMBL9895840 0.82 PTGDR2 (0.37) GRM2SUV39H2PTGDR2KDM4EALOX15
SCHEMBL9895107 0.82 MEN1 (0.36) CCR3GRM2CCR5CYP2D6TSHR
SCHEMBL9896143 0.82 GRM2 (0.38) CCR3GRM2CCR5
SCHEMBL9895913 0.81 GRM2 (0.36) CCR3GRM2CCR5
SCHEMBL9895760 0.80 GRM2 (0.37) CCR3GRM2PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975286-B2 Ether benzotriazole derivatives MERCK SHARP & DOHME CORP. (US) 2015-03-10 — — US claimed
US-20120149677-A1 ETHER BENZOTRIAZOLE DERIVATIVES MERCK SHARP & DOHME LLC 2012-06-14 — — US claimed
US-8975286-B2 Ether benzotriazole derivatives MERCK SHARP & DOHME CORP. (US) 2015-03-10 — — US disclosed
US-8975286-B2 Ether benzotriazole derivatives MERCK SHARP & DOHME CORP. (US) 2015-03-10 — — US disclosed
US-8975286-B2 Ether benzotriazole derivatives MERCK SHARP & DOHME CORP. (US) 2015-03-10 — — US disclosed
US-20120149677-A1 ETHER BENZOTRIAZOLE DERIVATIVES MERCK SHARP & DOHME LLC 2012-06-14 — — US disclosed
US-20120149677-A1 ETHER BENZOTRIAZOLE DERIVATIVES MERCK SHARP & DOHME LLC 2012-06-14 — — US disclosed
US-20120149677-A1 ETHER BENZOTRIAZOLE DERIVATIVES MERCK SHARP & DOHME LLC 2012-06-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149677-A1 ETHER BENZOTRIAZOLE DERIVATIVES GRM2, GRIA2, GRIK2 CCR3 3684/4885GRM2 1/4885SUV39H2 1081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.